Which Patients have Greatest Need for Elvitegravir/Cobicistat/Emtricitabine/TenofovirDF-Based Therapy?

Recent patents on anti-infective drug discovery

PubMedID: 25030944

Di Biagio A, Prinapori R, Taramasso L, Gustinetti G, Sticchi L, Bruzzone B, Viscoli C. Which Patients have Greatest Need for Elvitegravir/Cobicistat/Emtricitabine/TenofovirDF-Based Therapy?. Recent Pat Antiinfect Drug Discov. 2014;.
Elvitegravir/cobicistat/emtricitabine/tenofovir (EVG/COBI/FTC/TDF) is the new single-tablet, fixed-dose formulation containing an integrase strand transfer inhibitors recently approved as antiretroviral treatment. In this paper we analyze its use and advantages in naïve and experienced HIV-infected patients and we focused on special populations in which EVG/COBI/FTC/TDF could be a suitable option. Furthermore the manuscript reports the recent patent of EVG which may have an influence in the management of HIV-infected patients in the next future.